Bayer: Breakthrough Therapy Designation for BAY 2927088 for Non-Small Cell Lung Cancer

 

• BAY 2927088 is an oral, small molecule tyrosine kinase inhibitor under development as a potential new targeted therapy for patients with NSCLC harboring HER2 activating mutations
• Breakthrough Therapy designation is a process designed to expedite the development and review of investigational drugs that have potential to provide substantial improvement over available therapy in areas of high unmet medical need

https://www.biospace.com/article/releases/bayer-receives-u-s-fda-breakthrough-therapy-designation-for-bay-2927088-for-non-small-cell-lung-cancer-harboring-her2-activating-mutations/